sumatriptan with naprosyn
PreclinicalSmall molecule
sumatriptan with naprosyn is one of 10 small molecule programs targeting Migraine With Aura. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Migraine With Aura
#DrugCompanyPhaseTrials
1Marinol
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Rozerem
TakedaApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Viagra
VViatris Specialty LLC
Approved
Midamor
PPadagis LLC
Approved
Imitrex
GGlaxo Dba Glaxosmithkline
Preclinical
Topamax
WWim Janssens
Preclinical
Levcromakalim
DDanish Headache Center
Preclinical
sumatriptan with naprosyn
DDent Neurologic Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sumatriptan with naprosyn. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDent Neurologic Institute